RCEL — AVITA Medical Share Price
0.000.00%
Last trade - 00:00- $244.26m
- $250.62m
- $64.25m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 54.29 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.03% | ||
| Return on Equity | -230.96% | ||
| Operating Margin | -88.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 14.26 | 29.23 | 34.42 | 50.14 | 64.25 | 102.26 | 133.54 | 45.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
Directors
- Lou Panaccio NEC (64)
- Michael Perry CEO (61)
- Michael Holder CFO (59)
- Kathy McGee COO (56)
- Andrew Quick CTO (50)
- Donna Shiroma GCN (58)
- Erin Liberto OTH (47)
- Jeremy Cook NID (71)
- James Corbett NID (63)
- Suzanne Crowe NID (69)
- Louis Drapeau NID (77)
- Jan Reed NID (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 17th, 2020
- Public Since
- March 18th, 2012
- No. of Shareholders
- 19,321
- No. of Employees
- 260
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 26,434,658
- Address
- 28159 Avenue Stanford, Suite 220, VALENCIA, 91355
- Web
- https://www.avitamedical.com/
- Phone
- +1 6613679170
- Contact
- Jessica Ekeberg
- Auditors
- Grant Thornton LLP
Upcoming Events for RCEL
Q1 2025 AVITA Medical Inc Earnings Release
AVITA Medical Inc To Host Acute Wound Care Showcase
AVITA Medical Inc Annual Shareholders Meeting
AVITA Medical Inc Annual Shareholders Meeting
Q2 2025 AVITA Medical Inc Earnings Release
Similar to RCEL
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the AVITA Medical share price?
As of Today at 19:27 UTC, shares in AVITA Medical are trading at $9.24. This share price information is delayed by 15 minutes.
How has the AVITA Medical share price performed this year?
Shares in AVITA Medical last closed at $9.24 and the price had moved by +5.96% over the past 365 days. In terms of relative price strength the AVITA Medical share price has underperformed the S&P500 Index by -4.45% over the past year.
What are the analyst and broker recommendations for AVITA Medical?
The overall consensus recommendation for AVITA Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AVITA Medical dividend yield?
AVITA Medical does not currently pay a dividend.
Does AVITA Medical pay a dividend?
AVITA Medical does not currently pay a dividend.
When does AVITA Medical next pay dividends?
AVITA Medical does not currently pay a dividend.
How do I buy AVITA Medical shares?
To buy shares in AVITA Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AVITA Medical?
As of the previous close price of $9.24, shares in AVITA Medical had a market capitalisation of $244.26m.
Where are AVITA Medical shares listed?
Here are the trading details for AVITA Medical:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RCEL
What kind of share is AVITA Medical?
Based on an overall assessment of its quality, value and momentum AVITA Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AVITA Medical share price forecast for 2025?
The analyst consensus target price for shares in AVITA Medical is $17.50. That is 89.39% above the last closing price of $9.24.
Analysts covering AVITA Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.66 for the next financial year.
Find out moreWhat is the trend in the AVITA Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AVITA Medical. Over the past six months, its share price has underperformed the S&P500 Index by -9.88%.
As of the last closing price of $9.24, shares in AVITA Medical were trading -8.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AVITA Medical PE Ratio?
The AVITA Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AVITA Medical?
AVITA Medical's management team is headed by:
- Lou Panaccio - NEC
- Michael Perry - CEO
- Michael Holder - CFO
- Kathy McGee - COO
- Andrew Quick - CTO
- Donna Shiroma - GCN
- Erin Liberto - OTH
- Jeremy Cook - NID
- James Corbett - NID
- Suzanne Crowe - NID
- Louis Drapeau - NID
- Jan Reed - NID